SCHEMBL3768796

SCHEMBL3768796

CC(C)(C)OC(=O)CN[C@H](Cc1ccccc1-c1ccccc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.51
ACE P12821 2/20 0.47
MME P08473 1/20 0.47
CPA1 P15085 1/20 0.47
ACE2 Q9BYF1 1/20 0.47
PTPRC P08575 2/20 0.44
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
ITGA4 P13612 1/20 0.41
ITGB7 P26010 1/20 0.41
CTSS P25774 3/20 0.40
CTSK P43235 3/20 0.40
PTPN1 P18031 2/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
PTGER1 P34995 1/20 0.38
PTGER4 P35408 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
SCN9A Q15858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318009 0.84 CTSS (0.57) KMT2AACEMMECPA1ACE2
SCHEMBL27563011 0.84 CTSS (0.57) KMT2AACEMMECPA1ACE2
SCHEMBL3026223 0.83 ACE (0.54) ACEMMEACE2ITGA4ITGB7
SCHEMBL2476918 0.83 ACE (0.54) ACEMMEACE2ITGA4ITGB7
SCHEMBL3268059 0.83 ACE (0.54) ACEMMEACE2ITGA4ITGB7
SCHEMBL6170513 0.82 ACE (0.57) KMT2AACEMMECPA1ACE2
SCHEMBL503474 0.82 ACE (0.57) KMT2AACEMMECPA1ACE2
SCHEMBL6317207 0.78 CTSS (0.58) ACECTSSCTSK
SCHEMBL8553442 0.78 ACE (0.61) KMT2AACECTSSCTSKMAPT
SCHEMBL7434878 0.78 ACE (0.61) KMT2AACECTSSCTSKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054402-B1 AN AMINOISOQUINOLINE THROMBIN INHIBITOR WITH IMPROVED BIOAVAILABILITY MERCK SHARP & DOHME (NL) 2013-11-27 EP disclosed
US-8299091-B2 Aminoisoquinoline thrombin inhibitor with improved bioavailability MSD OSS B.V. (NL) 2012-10-30 US disclosed
US-20100305153-A1 AMINOISOQUINOLINE THROMBIN INHIBITOR WITH IMPROVED BIOAVAILABILITY N.V. ORGANON 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305153-A1 AMINOISOQUINOLINE THROMBIN INHIBITOR WITH IMPROVED BIOAVAILABILITY TFPI, TFPI2, PREP KMT2A 1386/4885ACE 105/4885MME 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.